These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

468 related articles for article (PubMed ID: 33016874)

  • 1. A powerful drug combination strategy targeting glutamine addiction for the treatment of human liver cancer.
    Jin H; Wang S; Zaal EA; Wang C; Wu H; Bosma A; Jochems F; Isima N; Jin G; Lieftink C; Beijersbergen R; Berkers CR; Qin W; Bernards R
    Elife; 2020 Oct; 9():. PubMed ID: 33016874
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glutamine Addiction in Kidney Cancer Suppresses Oxidative Stress and Can Be Exploited for Real-Time Imaging.
    Abu Aboud O; Habib SL; Trott J; Stewart B; Liang S; Chaudhari AJ; Sutcliffe J; Weiss RH
    Cancer Res; 2017 Dec; 77(23):6746-6758. PubMed ID: 29021138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ASCT2 overexpression is associated with poor survival of OSCC patients and ASCT2 knockdown inhibited growth of glutamine-addicted OSCC cells.
    Luo Y; Li W; Ling Z; Hu Q; Fan Z; Cheng B; Tao X
    Cancer Med; 2020 May; 9(10):3489-3499. PubMed ID: 32162845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting glutaminolysis has antileukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibition.
    Jacque N; Ronchetti AM; Larrue C; Meunier G; Birsen R; Willems L; Saland E; Decroocq J; Maciel TT; Lambert M; Poulain L; Hospital MA; Sujobert P; Joseph L; Chapuis N; Lacombe C; Moura IC; Demo S; Sarry JE; Recher C; Mayeux P; Tamburini J; Bouscary D
    Blood; 2015 Sep; 126(11):1346-56. PubMed ID: 26186940
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer.
    Gross MI; Demo SD; Dennison JB; Chen L; Chernov-Rogan T; Goyal B; Janes JR; Laidig GJ; Lewis ER; Li J; Mackinnon AL; Parlati F; Rodriguez ML; Shwonek PJ; Sjogren EB; Stanton TF; Wang T; Yang J; Zhao F; Bennett MK
    Mol Cancer Ther; 2014 Apr; 13(4):890-901. PubMed ID: 24523301
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glutaminase inhibition improves FLT3 inhibitor therapy for acute myeloid leukemia.
    Gregory MA; Nemkov T; Reisz JA; Zaberezhnyy V; Hansen KC; D'Alessandro A; DeGregori J
    Exp Hematol; 2018 Feb; 58():52-58. PubMed ID: 28947392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glutaminase inhibitor CB-839 increases radiation sensitivity of lung tumor cells and human lung tumor xenografts in mice.
    Boysen G; Jamshidi-Parsian A; Davis MA; Siegel ER; Simecka CM; Kore RA; Dings RPM; Griffin RJ
    Int J Radiat Biol; 2019 Apr; 95(4):436-442. PubMed ID: 30557074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resveratrol enhances cisplatin-induced apoptosis in human hepatoma cells via glutamine metabolism inhibition.
    Liu Z; Peng Q; Li Y; Gao Y
    BMB Rep; 2018 Sep; 51(9):474-479. PubMed ID: 30103844
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting glutamine-addiction and overcoming CDK4/6 inhibitor resistance in human esophageal squamous cell carcinoma.
    Qie S; Yoshida A; Parnham S; Oleinik N; Beeson GC; Beeson CC; Ogretmen B; Bass AJ; Wong KK; Rustgi AK; Diehl JA
    Nat Commun; 2019 Mar; 10(1):1296. PubMed ID: 30899002
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ASCT2 (SLC1A5) is an EGFR-associated protein that can be co-targeted by cetuximab to sensitize cancer cells to ROS-induced apoptosis.
    Lu H; Li X; Lu Y; Qiu S; Fan Z
    Cancer Lett; 2016 Oct; 381(1):23-30. PubMed ID: 27450723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pyruvate anaplerosis is a mechanism of resistance to pharmacological glutaminase inhibition in triple-receptor negative breast cancer.
    Singleton DC; Dechaume AL; Murray PM; Katt WP; Baguley BC; Leung EY
    BMC Cancer; 2020 May; 20(1):470. PubMed ID: 32450839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual inhibition of glutaminase and carnitine palmitoyltransferase decreases growth and migration of glutaminase inhibition-resistant triple-negative breast cancer cells.
    Reis LMD; Adamoski D; Ornitz Oliveira Souza R; Rodrigues Ascenção CF; Sousa de Oliveira KR; Corrêa-da-Silva F; Malta de Sá Patroni F; Meira Dias M; Consonni SR; Mendes de Moraes-Vieira PM; Silber AM; Dias SMG
    J Biol Chem; 2019 Jun; 294(24):9342-9357. PubMed ID: 31040181
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glutamine to proline conversion is associated with response to glutaminase inhibition in breast cancer.
    Grinde MT; Hilmarsdottir B; Tunset HM; Henriksen IM; Kim J; Haugen MH; Rye MB; Mælandsmo GM; Moestue SA
    Breast Cancer Res; 2019 May; 21(1):61. PubMed ID: 31088535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of the interactions of potent allosteric inhibitors with glutaminase C, a key enzyme in cancer cell glutamine metabolism.
    Huang Q; Stalnecker C; Zhang C; McDermott LA; Iyer P; O'Neill J; Reimer S; Cerione RA; Katt WP
    J Biol Chem; 2018 Mar; 293(10):3535-3545. PubMed ID: 29317493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting Glutamine Metabolism and Redox State for Leukemia Therapy.
    Gregory MA; Nemkov T; Park HJ; Zaberezhnyy V; Gehrke S; Adane B; Jordan CT; Hansen KC; D'Alessandro A; DeGregori J
    Clin Cancer Res; 2019 Jul; 25(13):4079-4090. PubMed ID: 30940653
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of the MYC-Regulated Glutaminase Metabolic Axis Is an Effective Synthetic Lethal Approach for Treating Chemoresistant Ovarian Cancers.
    Shen YA; Hong J; Asaka R; Asaka S; Hsu FC; Suryo Rahmanto Y; Jung JG; Chen YW; Yen TT; Tomaszewski A; Zhang C; Attarwala N; DeMarzo AM; Davidson B; Chuang CM; Chen X; Gaillard S; Le A; Shih IM; Wang TL
    Cancer Res; 2020 Oct; 80(20):4514-4526. PubMed ID: 32859605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The glutaminase inhibitor telaglenastat enhances the antitumor activity of signal transduction inhibitors everolimus and cabozantinib in models of renal cell carcinoma.
    Emberley E; Pan A; Chen J; Dang R; Gross M; Huang T; Li W; MacKinnon A; Singh D; Sotirovska N; Steggerda SM; Wang T; Parlati F
    PLoS One; 2021; 16(11):e0259241. PubMed ID: 34731180
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-tumor effects of an antagonistic mAb against the ASCT2 amino acid transporter on KRAS-mutated human colorectal cancer cells.
    Hara Y; Minami Y; Yoshimoto S; Hayashi N; Yamasaki A; Ueda S; Masuko K; Masuko T
    Cancer Med; 2020 Jan; 9(1):302-312. PubMed ID: 31709772
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A facile and sensitive method of quantifying glutaminase binding to its inhibitor CB-839 in tissues.
    Chen Y; Zhao Y; Bajor DL; Wang Z; Selfridge JE
    J Genet Genomics; 2020 Jul; 47(7):389-395. PubMed ID: 33004309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glutaminase inhibitor CB-839 synergizes with carfilzomib in resistant multiple myeloma cells.
    Thompson RM; Dytfeld D; Reyes L; Robinson RM; Smith B; Manevich Y; Jakubowiak A; Komarnicki M; Przybylowicz-Chalecka A; Szczepaniak T; Mitra AK; Van Ness BG; Luczak M; Dolloff NG
    Oncotarget; 2017 May; 8(22):35863-35876. PubMed ID: 28415782
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.